m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05888
 [1]
Non-coding RNA HOXB-AS1 ELAVL1  lncRNA       miRNA   circRNA Direct Enhancement m6A modification FUT4 FUT4 ELAVL1 : m6A sites
m6A Modification:
m6A Regulator ELAV-like protein 1 (ELAVL1) READER
 Regulator Info 
m6A Target Alpha-(1,3)-fucosyltransferase 4 (FUT4)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator HOXB cluster antisense RNA 1 (HOXB-AS1) LncRNA View Details
Regulated Target ELAV-like protein 1 (HuR/ELAVL1) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary HOXB-AS1 obstruction suppressed MM cell proliferation, and stimulated cell apoptosis. In addition, HOXB-AS1 could modulate Alpha-(1,3)-fucosyltransferase 4 (FUT4) and FUT4-mediated Wnt/beta-catenin pathway. HOXB-AS1 enhanced the interaction between ELAVL1 and FUT4 so as to stabilize FUT4 messenger RNA.
Responsed Disease Multiple myeloma ICD-11: 2A83
 Disease Info 
Cell Process Cell proliferation
Cell apoptosis
RNA stability
In-vitro Model
 U-1996 Plasma cell myeloma Homo sapiens CVCL_M495
KM-3 Childhood B acute lymphoblastic leukemia Homo sapiens CVCL_0011
NCI-H929 Plasma cell myeloma Homo sapiens CVCL_1600
U266 (Human multiple myeloma cells)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Alpha-(1,3)-fucosyltransferase 4 (FUT4) 1 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name 99mTc-fanolesomab Approved [2]
Synonyms
LeuTech; NeutroSpec; RB5-IgM; Technetium (99mTc) fanolesomab; Anti-SSEA-1; Technetium-99m-fanolesomab; 99mTc RB5-IgM; 99mTc anti-SSEA-1; 99mTc-labeled anti-CD15 antibody
    Click to Show/Hide
External Link
TTD: D07WLI
2A83: Multiple myeloma 259 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Talquetamab Approved [3]
External Link
TTD: DXR1A6
 Compound Name Dostarlimab Approved [4]
External Link
TTD: DGQU43
 Compound Name Belantamab mafodotin Approved [5]
External Link
TTD: D52NZX
 Compound Name Elranatamab Approved [6]
Synonyms
PF-06863135
    Click to Show/Hide
External Link
TTD: D3KO5Y
 Compound Name Atezolizumab Approved [7]
External Link
TTD: D0YM2K
 Compound Name Metadoxine Approved [8]
Synonyms
MG01CI; Metadoxine (oral sustained release, ADHD); Metadoxine (oral extended release, ADHD), Alcobra; Metadoxine (oral sustained release, ADHD), Alcobra
    Click to Show/Hide
External Link
CID: 115198
TTD: D0YH0N
 Compound Name Ixazomib Approved [9]
External Link
CID: 25183872
TTD: D0Y2SW
DrugBank: DB09570
 Compound Name Thalidomide Approved [10]
Synonyms
Algosediv; Asmadion; Asmaval; Bonbrain; Bonbrrin; Calmore; Calmorex; Contergan; Corronarobetin; Distaval; Distaxal; Distoval; Ectiluran; Enterosediv; Gastrinide; Glupan; Glutanon; Grippex; Hippuzon; Imidene; Isomin; Kedavon; Kevadon; Neaufatin; Neosedyn; Neosydyn; Nerosedyn; Neufatin; Neurodyn; Neurosedin; Neurosedym; Neurosedyn; Nevrodyn; Nibrol; Noctosediv; Noxodyn; Pangul; Pantosediv; Polygripan; Profarmil; Psycholiquid; Psychotablets; Quetimid; Quietoplex; Sandormin; Sedalis; Sedimide; Sedin; Sedisperil; Sedoval; Shinnibrol; Sleepan; Slipro; Softenil; Softenon; Synovir; Talargan; Talidomida; Talidomide; Talimol; Talismol; Talizer; Telagan; Telargan; Telargean; Tensival; Thaled; Thalidomidum; Thalin; Thalinette; Thalomid; Thalomide; Theophilcholine; Valgis; Valgraine; Yodomin; Celgene Brand of Thalidomide; Talidomide [DCIT]; Thalidomide Celgene; Thalidomide Pharmion; Asidon 3; ENMD 0995; IN1061; Thalidomine USP26; Alpha-Phthalimidoglutarimide; E-217; Imida-lab; Imidan (peyta); N-Phthalimidoglutamic acid imide; N-Phthaloylglutamimide; N-Phthalylglutamic acid imide; Poly-Giron; Predni-Sediv; Pro-Bam M; Pro-ban M; Sedalis sedi-lab; Shin-naito S; THALIDOMIDE (AIDS INITIATIVE); Talidomida [INN-Spanish]; Thaled (TN); Thalidomide (soluble form); Thalidomidum [INN-Latin]; Thalomid (TM); Thalomid (TN); Thalomid, Thalidomide; Alpha-N-Phthalylglutaramide; Thalidomide [USAN:INN:BAN]; Alpha-(N-Phthalimido)glutarimide; N-Phthalyl-glutaminsaeure-imid; N-Phthalyl-glutaminsaeure-imid [German]; Thalidomide (+ and-); Thalidomide (JAN/USP/INN); N-(2,6-Dioxo-3-piperidyl)phthalimide; (+)-Thalidomide; (+-)-Thalidomide; (+/-)-THALIDOMIDE; (inverted question mark)-Thalidomide; 2,6-Dioxo-3-phthalimidopiperidine; 3-Phthalimidoglutarimide
    Click to Show/Hide
External Link
CID: 5426
TTD: D0U7GK
DrugBank: DB01041
 Compound Name Motixafortide Approved [11]
External Link
CID: 91865076
TTD: D0T6CN
DrugBank: DB14939
 Compound Name Bortezomib Approved [12]
Synonyms
179324-69-7; Velcade; Bortezomib (PS-341); UNII-69G8BD63PP; N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE; MLN-341; [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid; [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; CHEMBL325041; 69G8BD63PP; Boronic acid,; DPBA; PROSCRIPT BORONIC ACID; LPD 341; LPD-341; VELCADE (TN); Pyz-Phe-boroLeu; Bortezomib(JAN/USAN/INN); Velcade, MG-341, PS-341, Bortezomib; N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide; Bortezomib (Proteasome inhibitor); Peptide boronate
    Click to Show/Hide
External Link
CID: 387447
TTD: D0SH3I
DrugBank: DB00188
 Compound Name Daratumumab Approved [13]
External Link
TTD: D0RV4P
 Compound Name Lenalidomide Approved [14]
Synonyms
Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
    Click to Show/Hide
External Link
CID: 216326
TTD: D0Q5NX
DrugBank: DB00480
 Compound Name Isatuximab Approved [15]
External Link
TTD: D0JB2J
 Compound Name Dasatinib Approved [16]
Synonyms
Sprycel (TN); BMS 354825; BMS-354825; BMS-354825, Sprycel, BMS354825, Dasatinib; BMS354825; Dasatinib (USAN); Dasatinib [USAN]; Dasatinib anhydrous; Dasatinib, BMS 354825; Dasatinibum; Sprycel; Spyrcel
    Click to Show/Hide
External Link
CID: 3062316
TTD: D0E6XR
DrugBank: DB01254
 Compound Name Panobinostat Approved [17]
Synonyms
Faridak; LBH 589; LBH589; LBH-589; LBH-589B; NVP-LBH589; NVP-LBH-589; Panobinostat, NVP-LBH589, LBH589; (E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE; (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
    Click to Show/Hide
External Link
CID: 6918837
TTD: D0E3SH
DrugBank: DB06603
 Compound Name Siltuximab Approved [7]
External Link
TTD: D07NJN
 Compound Name Elotuzumab Approved [18]
Synonyms
BMS-901608
    Click to Show/Hide
External Link
TTD: D05DZR
 Compound Name Idecabtagene vicleucel Approved [19]
Synonyms
Bb2121
    Click to Show/Hide
External Link
TTD: D03NPI
 Compound Name Sirolimus Approved [20]
Synonyms
53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
    Click to Show/Hide
External Link
CID: 5284616
TTD: D03LJR
DrugBank: DB00877
 Compound Name Cerivastatin Approved [21]
Synonyms
Baycol; cerivastatin acid; Lipobay; 145599-86-6; Cerivastatin [INN:BAN]; UNII-AM91H2KS67; CHEBI:3558; AM91H2KS67; HSDB 7357; (3R,5S,6E)-7-(4-(p-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl)-3,5-dihydroxy-6-heptenoic acid; (3R,5S,6E)-7-(4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-6-heptenoic acid; 143201-11-0; 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (3R,5S,6E)-; Statins
    Click to Show/Hide
External Link
CID: 446156
TTD: D03KIA
DrugBank: DB00439
 Compound Name Teclistamab Approved [22]
External Link
TTD: D03AFF
 Compound Name Futibatinib Phase 1/2 [23]
External Link
CID: 71621331
TTD: D01ZLU
DrugBank: DB15149
 Compound Name Romiplostim Approved [24]
External Link
CID: 5329098
TTD: D01PZD
DrugBank: DB06436
 Compound Name MLN9708 Approved [25]
External Link
CID: 49867936
TTD: D01MML
 Compound Name Melphalan flufenamide Approved [26]
Synonyms
J-1; Dipeptide-conjugated melphalan prodrug (iv formulation, ovary tumor), Oncopeptides
    Click to Show/Hide
External Link
CID: 9935639
TTD: D01HPY
 Compound Name Carfilzomib Approved [27]
Synonyms
868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide
    Click to Show/Hide
External Link
CID: 11556711
TTD: D00UVA
DrugBank: DB08889
 Compound Name Nivolumab Approved [7]
External Link
TTD: D00GOV
 Compound Name Melphalan Approved [28]
Synonyms
Alkeran; Levofalan; Levofolan; Levopholan; Melfalan; Melfalano; Melphalanum; Alanine Nitrogen Mustard; Phenylalanine mustard; Phenylalanine nitrogen mu stard; Phenylalanine nitrogen mustard; AY3360000; CB 3025; ALKERAN (TN); At-290; CB-3025; L-PAM; L-Phenylalanine mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Melfalano [INN-Spanish]; Melphalanum [INN-Latin]; SK-15673; TRANSGENIC MODEL EVALUATION (MELPHALAN); MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN)); P-L-Sarcolysin; P-L-sarcolysine; TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN); Melphalan (JP15/USP/INN); Melphalan [USAN:INN:BAN:JAN]; P-Bis(beta-chloroethyl)aminophenylalanine; P-N-Di(chloroethyl)aminophenylalanine; P-N-di(chloroethyl)aminophenylala nine; P-Di-(2-chloroethyl)amino-L-phenylalanine; P-N-Bis(2-chloroethyl)amino-L-phenylalanine; L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine; P-N,N-bis(2-chloroethyl)amino-L-phenylalanine; (2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid; (2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid; 3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine; 3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine; 3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine; 4-(Bis(2-chloroethyl)amino)-L-phenylalanine; 4-[Bis(2-chloroethyl)amino]-L-phenylalanine; 4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
    Click to Show/Hide
External Link
CID: 460612
TTD: D00FGO
DrugBank: DB01042
 Compound Name Trapidil Phase 4 [21]
Synonyms
Trapymin; Rocornal; 15421-84-8; Avantrin; Trapymine; N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine; AR 12008; Trapidilum [INN-Latin]; UNII-EYG5Y6355E; EINECS 239-434-2; BRN 0186842; 7-Diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine; MLS000567667; EYG5Y6355E; N,N-Diethyl-5-methyl-(1,2,4)triazolo(1,5-a)pyrimidine-7-amine; (1,2,4)Triazolo(1,5-a)pyrimidin-7-amine, N,N-diethyl-5-methyl-; 5-Methyl-7-diethylamino-s-triazolo-(1,5-a)-pyrimidine; NCGC00016715-01; AR-12008; SMR000154170; SU10991
    Click to Show/Hide
External Link
CID: 5531
TTD: D0U2CV
DrugBank: DB09283
 Compound Name Ciltacabtagene autoleucel Phase 3 [29]
Synonyms
JNJ-68284528
    Click to Show/Hide
External Link
TTD: DXV06E
 Compound Name ABC294640 Phase 3 [7]
Synonyms
915385-81-8; Opaganib; ABC-294640; CHEMBL2158685; ABC 294640; UNII-DRG21OQ517; DRG21OQ517; Yeliva; SCHEMBL1548333; GTPL6624; CHEBI:124965; MolPort-044-560-286; HMS3402P05; BCP08959; EX-A1962; BDBM50393642; 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide; AKOS027327311; CS-0877; SB17167; DB12764; API0017247; HY-16015; S7174; BRD-A70814879-003-01-8
    Click to Show/Hide
External Link
CID: 15604015
TTD: D0X6BX
DrugBank: DB12764
 Compound Name Tabalumab Phase 3 [30]
Synonyms
LY2127399
    Click to Show/Hide
External Link
TTD: D0U6UK
 Compound Name Marizomib Phase 1 [31]
Synonyms
salinosporamide A; 437742-34-2; (-)-Salinosporamide A; UNII-703P9YDP7F; NPI-0052; NPI 0052; ML 858; 703P9YDP7F; CHEBI:48045; (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-(1S)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; Marizomib [USAN:INN]; marizomibum; Marizomib (USAN/INN); Salinosporamide A (NPI-0052, Marizomib); SCHEMBL151667; CHEMBL371405; NGWSFRIPKNWYAO-SHTIJGAHSA-N; ZINC3990364; BDBM50398608; 2531AH; AKOS027323566; DB11762; Z-3093; D09640; 855517-10-1
    Click to Show/Hide
External Link
CID: 11347535
TTD: D0N0RN
DrugBank: DB11762
 Compound Name Galinpepimut-S Phase 3 [7]
External Link
TTD: D0M9OO
 Compound Name Ulocuplumab Phase 3 [32]
External Link
TTD: D0C3LQ
 Compound Name Pelareorep Phase 2 [33]
External Link
TTD: D0BF8Y
 Compound Name NVP-LAQ824 Phase 3 [21]
Synonyms
Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539
    Click to Show/Hide
External Link
CID: 6445533
TTD: D0B3FV
 Compound Name Plitidepsin Phase 3 [31]
Synonyms
Aplidin (TN)
    Click to Show/Hide
External Link
CID: 9812534
TTD: D07QJK
DrugBank: DB04977
 Compound Name Oblimersen Phase 3 [34]
External Link
CID: 118984457
TTD: D05RJP
 Compound Name T89 Phase 3 [35]
Synonyms
2-Propanone, 1-(5-nitro-2H-tetrazol-2-yl)-; 131394-19-9; 1-(5-nitro-1,2,3,4-tetraazol-2-yl)acetone; ZERO/000247; AC1LOTQU; ACMC-20mu2z; 2-acetonyl-5-nitrotetrazole; CTK0C0970; DTXSID40361521; MolPort-001-904-996; ZINC1084291; STK760073; SBB000169; AKOS000558886; MCULE-5436124308; 1-(5-nitrotetrazol-2-yl)propan-2-one; 2-(2-Oxopropyl)-5-nitro-2H-tetrazole; ST026974; ST023819; BAS 01313849; 1-(5-Nitro-tetrazol-2-yl)-propan-2-one; EU-0085349; 1-(5-nitro-2H-tetrazol-2-yl)propan-2-one; SR-01000523987; SR-01000523987-1
    Click to Show/Hide
External Link
CID: 1270252
TTD: D05QUL
 Compound Name GMI-1271 Phase 3 [7]
Synonyms
Uproleselan
    Click to Show/Hide
External Link
CID: 71600085
TTD: D03PWD
DrugBank: DB14829
 Compound Name Selinexor Phase 3 [7]
Synonyms
Xpovio; KPT 330; KPT-330; KPT-330(Selinexor); KPT330;Selinexor; 1393477-72-9; 31TZ62FO8F; CHEMBL3545185; SCHEMBL14678327; Selinexor (KPT-330); Selinexor [USAN:INN]; Tube706; UNII-31TZ62FO8F
    Click to Show/Hide
External Link
CID: 71481097
TTD: D00LNW
DrugBank: DB11942
 Compound Name Imetelstat Phase 2 [36]
Synonyms
Motesanib diphosphate; 857876-30-3; Motesanib (Diphosphate); Motesanib Diphosphate (AMG-706); UNII-T6Q3060U91; Motesanib diphosphate [USAN]; T6Q3060U91; Motesanib diphosphate (USAN); AMG-706 diphosphate; Motesanib phosphate (JAN); bis(phosphoric acid); Motesanib Diphosphate/AMG-706; CHEMBL2107357; DTXSID30235080; C22H29N5O9P2; MolPort-016-633-170; HMS3654K07; AOB87339; ABP000867; AKOS026750408; CS-0193; API0006359; AN-5306; SB16584; RL05311; AS-17019; HY-10229; SW218300-2; FT-0672543; X7466; D08947; W-5527; A841448
    Click to Show/Hide
External Link
CID: 71587831
TTD: D04XEQ
 Compound Name CLR 131 Phase 1 [31]
External Link
TTD: DNCA54
 Compound Name Descartes-11 Phase 2 [37]
External Link
TTD: DN28SH
 Compound Name DKN-01 Phase 2 [38]
External Link
TTD: DMF73Z
 Compound Name RAPA-201 Phase 2 [39]
External Link
TTD: DL7J8B
 Compound Name BHQ880 Phase 2 [40]
Synonyms
BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis
    Click to Show/Hide
External Link
TTD: D62FLA
 Compound Name INCB00928 Phase 2 [41]
External Link
TTD: D50OLM
 Compound Name Descartes-08 Phase 2 [42]
External Link
TTD: D0Z6AR
 Compound Name GSK2857916 Phase 2 [7]
External Link
TTD: D0YV0N
 Compound Name Delanzomib Phase 2 [43]
Synonyms
((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid; s1157; ZINC202536926; SB16695; SW219161-1; boronic acid, b-[(1r)-1-[[(2s,3r)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-
    Click to Show/Hide
External Link
CID: 24800541
TTD: D0VO0T
DrugBank: DB11956
 Compound Name Myeloma cancer vaccine Phase 2 [44]
External Link
TTD: D0U0NS
 Compound Name CJM112 Phase 2 [7]
External Link
TTD: D0T5TN
 Compound Name Tanespimycin Discontinued in Phase 3 [45]
Synonyms
CNF-101; [(3S,5S,6R,7S,8E,10R,11S,12E,14E)-6-Hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-8,12,14,18,21-pentaen-10-yl] carbamate; [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate; 17AAG, Tanespimycin, Geldanamycin, NSC330507, 17-(Allylamino)-17-demethoxygeldanamycin, CP 127374
    Click to Show/Hide
External Link
CID: 6505803
TTD: D0SC2J
DrugBank: DB05134
 Compound Name CLR-131 Phase 2 [7]
External Link
TTD: D0RX6F
 Compound Name CDX-301 Phase 2 [7]
External Link
TTD: D0Q8CV
 Compound Name BI-505 Phase 2 [31]
External Link
TTD: D0Q7OE
 Compound Name SurVaxM Phase 2 [46]
External Link
TTD: D0KQ8W
 Compound Name LCAR-B38M CAR-T Cell Phase 2 [47]
External Link
TTD: D0K1AK
 Compound Name CART-19 cells Phase 2 [48]
External Link
TTD: D0I0NJ
 Compound Name ALT-803 Phase 2 [7]
Synonyms
IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
    Click to Show/Hide
External Link
TTD: D0FD7H
 Compound Name LCL161 Phase 2 [7]
External Link
CID: 24737642
TTD: D09MIN
DrugBank: DB12085
 Compound Name mab 1-7F9 Phase 2 [49]
External Link
TTD: D08XPN
 Compound Name JNJ 63723283 Phase 2 [7]
External Link
TTD: D08UGS
 Compound Name GSK3377794 Phase 2 [7]
External Link
TTD: D08FWJ
 Compound Name GL-0817 Phase 2 [50]
Synonyms
912762-70-0; MolPort-002-506-765; tert-butyl N-[(2Z)-2-(2,4-dimethoxyphenyl)-2-(hydroxyimino)ethyl]carbamate; ZINC103473003; AKOS005256100; [2-(2,4-DIMETHOXY-PHENYL)-2-HYDROXYIMINO-ETHYL]-CARBAMIC ACID TERT-BUTYL ESTER
    Click to Show/Hide
External Link
CID: 122706930
TTD: D08DUF
 Compound Name ONC201 Phase 2 [7]
Synonyms
Onc-201; TIC10; 1616632-77-9; UNII-9U35A31JAI; 9U35A31JAI; TIC10(ONC-201); 7-Benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5(4H)-one; TIC 10 active isomer; ONC201(TIC10 isomer); TIC 10; GTPL9978; SCHEMBL16227974; EX-A669; ONC 201; AOB2892; MolPort-039-137-731; HY-15615A; 3388AH; s7963; ZINC169620396; AKOS025404904; NSC 350625; CS-3564; AS-16735; AK174891; KB-335104; FT-0700231; J-690224; 1342897-86-2; 2,4,6,7,8,9-Hexahydro-4-((2-methylphenyl)methyl)-7-phenylmethyl)imidazo)(1,2-a)pyrido(3,4-e)pyrimid
    Click to Show/Hide
External Link
CID: 73777259
TTD: D07XQS
DrugBank: DB14844
 Compound Name Selinexor Approved [20]
External Link
CID: 71481097
TTD: D07KVV
DrugBank: DB11942
 Compound Name Thalidomide Approved [51]
External Link
CID: 5426
TTD: D07ISX
DrugBank: DB01041
 Compound Name Bb2121 Phase 2 [7]
External Link
TTD: D07CUR
 Compound Name PVX-410 Phase 2 [46]
External Link
TTD: D06DUS
 Compound Name Rocilinostat Phase 2 [52]
Synonyms
1316214-52-4; Rocilinostat (ACY-1215); 2-(Diphenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-WKT909C62B; ACY-63; WKT909C62B; 2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; AK151416; N-[7-(hydroxyamino)-7-oxoheptyl]-2-(N-phenylanilino)pyrimidine-5-carboxamide; 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; Ricolinostat [USAN:INN]; AH4; Ricolinostat (USAN/INN); MLS006011181; SCHEMBL574580; GTPL7010
    Click to Show/Hide
External Link
CID: 53340666
TTD: D05KED
DrugBank: DB12376
 Compound Name NVP-AUY922 Phase 2 [53]
Synonyms
Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide
    Click to Show/Hide
External Link
CID: 135539077
TTD: D05BYA
 Compound Name ARRY-520 Phase 2 [31]
Synonyms
Filanesib; 885060-09-3; UNII-8A49OSO368; Arry520; CHEMBL2347655; ARRY 520 trifluoroacetate; 8A49OSO368; ARRY 520; (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide; Filanesib [INN]; Filanesib [USAN:INN]; C20H22F2N4O2S; 1385020-40-5; Filanesib(ARRY-520); SCHEMBL368043; DTXSID50237086; EX-A678; BCP07442; ZINC43204022; 3452AH; BDBM50431893; AKOS030526964; SB19209; RL05514; CS-0867; NCGC00381751-02; NCGC00381751-04
    Click to Show/Hide
External Link
CID: 44224257
TTD: D04VWJ
DrugBank: DB06040
 Compound Name BT-062 Phase 2 [7]
External Link
TTD: D04PUI
 Compound Name Captisol-enabled Melphalan Phase 2 [54]
External Link
TTD: D04LXB
 Compound Name IPH-2101 Phase 2 [55]
External Link
TTD: D04IXD
 Compound Name Darinaparsin Phase 2 [56]
Synonyms
ZIO-101
    Click to Show/Hide
External Link
CID: 11683005
TTD: D03ZME
DrugBank: DB06179
 Compound Name Ficlatuzumab Phase 2 [57]
Synonyms
AV-299
    Click to Show/Hide
External Link
TTD: D03UBW
 Compound Name GVAX Phase 2 [58]
External Link
TTD: D03OSE
 Compound Name INK128 Phase 2 [59]
Synonyms
1224844-38-5; Sapanisertib; INK-128; INK 128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; JGH0DF1U03; 5-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)benzo[d]oxazol-2-amine; INK-0128; 3-(2-Amino-5-benzoxazolyl)-1-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine; C15H15N7O; 5-(4-amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine; 5-(4-Amino-1-isopropyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)benzo[d]oxazol-2-amine; Sapanisertib (USAN/INN)
    Click to Show/Hide
External Link
CID: 45375953
TTD: D03DPZ
DrugBank: DB11836
 Compound Name GSK2110183 Phase 2 [60]
External Link
CID: 46843057
TTD: D02NXM
DrugBank: DB11648
 Compound Name Oprozomib Phase 1 [7]
External Link
CID: 25067547
TTD: D02BLD
DrugBank: DB11991
 Compound Name CC-220 Phase 1 [7]
Synonyms
AC1OEW2H; NPD6561; MCULE-9299015048; BCP9000573; BCP0726000266
    Click to Show/Hide
External Link
CID: 67335295
TTD: D01XVX
DrugBank: DB12101
 Compound Name Ygalo Phase 2 [7]
External Link
TTD: D01CBE
 Compound Name Indatuximab ravtansine Phase 2 [61]
External Link
TTD: D00CQI
 Compound Name REGN5459 Phase 1/2 [62]
External Link
TTD: DY9G1D
 Compound Name REGN5458 Phase 1/2 [63]
External Link
TTD: DR7Q5N
 Compound Name ISB 1342 Phase 1/2 [64]
Synonyms
GBR1342
    Click to Show/Hide
External Link
TTD: DE0L6O
 Compound Name PBCAR269A Phase 1/2 [65]
External Link
TTD: D7LU8R
 Compound Name NEXI-002 Phase 1/2 [66]
External Link
TTD: D6EI9F
 Compound Name Tinostamustine Phase 1/2 [67]
Synonyms
1236199-60-2; 1H-Benzimidazole-2-heptanamide, 5-(bis(2-chloroethyl)amino)-N-hydroxy-1-methyl-; 1H-Benzimidazole-2-heptanamide, 5-[bis(2-chloroethyl)amino]-N-hydroxy-1-methyl-; 29DKI2H2NY; 7-(5-(bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-hydroxyheptanamide; 7-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-N-hydroxyheptanamide; 7-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}-N-hydroxyheptanamide; AKOS030526024; BCP20331; BDBM50569838; BE170657; CHEMBL3989941; CS-6484; D11182; DB15147; E76854; EDO-S 101; EDO-S101; EDO-S-101; EX-A1322; HY-101780; Minomustine; MS-27198; S8769; SB19172; SCHEMBL7915449; starbld0018955; Tinostamustine; Tinostamustine (USAN/INN); TINOSTAMUSTINE [INN]; Tinostamustine [USAN]; TINOSTAMUSTINE [WHO-DD]; Tinostamustine(EDO-S101); UNII-29DKI2H2NY
    Click to Show/Hide
External Link
CID: 46836227
TTD: D39TVC
DrugBank: DB15147
 Compound Name Modakafusp alfa Phase 1/2 [68]
Synonyms
TAK-573
    Click to Show/Hide
External Link
TTD: D1B3VP
 Compound Name SL-401 Phase 1/2 [7]
External Link
TTD: D0Z2ZY
 Compound Name Milatuzumab-doxorubicin conjugate Phase 1/2 [69]
External Link
TTD: D0Y6BO
 Compound Name CART-138 cells Phase 1/2 [70]
External Link
TTD: D0Y4MA
 Compound Name CAR-T cells targeting CD30 Phase 1/2 [71]
External Link
TTD: D0UA0U
 Compound Name CD56 CAR T cells Phase 1/2 [72]
External Link
TTD: D0U1GP
 Compound Name NY-ESO-TCR Phase 1/2 [33]
External Link
TTD: D0TN1N
 Compound Name CAR-T cells targeting CD22 Phase 1/2 [71]
External Link
TTD: D0PD4C
 Compound Name Anti-CD38 CAR-T cells Phase 1/2 [73]
External Link
TTD: D0OO1S
 Compound Name MOR-202 Phase 1/2 [74]
Synonyms
Anti-CD38 antibodies, MorphoSys; HuCAL-mAb1, MorphoSys; HuCAL-mAb2, MorphoSys; HuCAL-mAb3, MorphoSys
    Click to Show/Hide
External Link
TTD: D0O4IN
 Compound Name BIW-8962 Phase 1/2 [75]
External Link
TTD: D0N6TD
 Compound Name Anti-BCMA CAR-T cells Phase 1/2 [73]
External Link
TTD: D0MK7H
 Compound Name CART-138 cells Phase 1/2 [76]
External Link
TTD: D0M3RI
 Compound Name Anti-NY-ESO-1 CAR-T cells Phase 1/2 [73]
External Link
TTD: D0LJ2S
 Compound Name CC-92480 Phase 1/2 [77]
Synonyms
CELMoD
    Click to Show/Hide
External Link
TTD: D0HT4Y
 Compound Name CD38 and BCMA CAR-T Cells Phase 1/2 [78]
External Link
TTD: D0G0PI
 Compound Name JCARH125 Phase 1/2 [79]
External Link
TTD: D0EQ6D
 Compound Name CAR-T cells targeting CLL1 Phase 1/2 [71]
External Link
TTD: D0DO8E
 Compound Name BION-1301 Phase 1/2 [7]
External Link
TTD: D0DJ2H
 Compound Name Atiprimod Phase 1/2 [21]
Synonyms
Atiprimod [INN]; SKF 106615; SKF-106615; N,N-Diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine; 3-(8,8-dipropyl-3-azaspiro[4.5]decan-3-yl)-N,N-diethylpropan-1-amine
    Click to Show/Hide
External Link
CID: 129869
TTD: D0D9LJ
DrugBank: DB05513
 Compound Name CAR-T cells targeting BCMA Phase 1/2 [71]
External Link
TTD: D0D4ZN
 Compound Name AUTO2 Phase 1/2 [80]
External Link
TTD: D0B8UW
 Compound Name CART-19/BCMA Phase 1/2 [81]
External Link
TTD: D0AC9S
 Compound Name CD38 CAR T cells Phase 1/2 [72]
External Link
TTD: D09UFZ
 Compound Name P-BCMA-101 Phase 1/2 [82]
External Link
TTD: D09JKN
 Compound Name JCAR017 Phase 1 [79]
External Link
TTD: D08BPS
 Compound Name Anti-BCMA-CAR-transduced T cells Phase 1/2 [83]
External Link
TTD: D07QIQ
 Compound Name JNJ-68284528 Phase 1/2 [84]
External Link
TTD: D07PJS
 Compound Name AR-42 Phase 1/2 [85]
Synonyms
935881-37-1; OSU-HDAC42; AR 42; (S)-HDAC-42; (S)-N-Hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide; UNII-E0GG29V0AQ; (S)-HDAC 42; E0GG29V0AQ; AR42; HDAC-42; AR-42 (HDAC-42); N-hydroxy-4-{[(2S)-3-methyl-2-phenylbutanoyl]amino}benzamide; N-hydroxy-4-[[(2S)-3-methyl-2-phenylbutanoyl]amino]benzamide; AR-42 (OSU-HDAC42); AC1OCFYN; cc-20; OSU-HDAC 42; MLS006011089; CHEMBL191482; SCHEMBL2348844; OSU-42; DTXSID4042678; NOCAS_42678; CTK8C1969; AOB3995; N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide; MolPort-009-019-571
    Click to Show/Hide
External Link
CID: 6918848
TTD: D07KDI
DrugBank: DB12707
 Compound Name LGH-447 Phase 1/2 [86]
External Link
CID: 44814409
TTD: D07EHV
DrugBank: DB14943
 Compound Name CWP232291 Phase 1/2 [7]
External Link
TTD: D07AYI
 Compound Name CD138 CAR T cells Phase 1/2 [72]
External Link
TTD: D05CTQ
 Compound Name ImMucin Phase 1/2 [87]
Synonyms
MUC-1 peptide vaccine (cancer), Vaxil BioTherapeutics/Hadassah Medical
    Click to Show/Hide
External Link
TTD: D04UFI
 Compound Name CART-BCMA cells Phase 1/2 [70]
External Link
TTD: D04PIU
 Compound Name CAR-T cells targeting CD19 Phase 1/2 [71]
External Link
TTD: D04JHH
 Compound Name BCMA CAR-T Phase 1/2 [88]
External Link
TTD: D02JNC
 Compound Name BCMA CAR T cells Phase 1/2 [72]
External Link
TTD: D01CUC
 Compound Name CC-98633 Phase 1 [89]
External Link
TTD: DX6J8M
 Compound Name BCMA-CS1 cCAR Phase 1 [90]
External Link
TTD: DX1LD3
 Compound Name TNB-383B Phase 1 [91]
External Link
TTD: DW1H9O
 Compound Name 131I-labelled CLR1404 Phase 1 [92]
External Link
TTD: DVR84A
 Compound Name GPRC5D CAR-T cell therapy Phase 1 [93]
External Link
TTD: DV9M0Y
 Compound Name AMG 420 Phase 1 [7]
External Link
TTD: DUZ0F7
 Compound Name BCMA-CD19 cCAR Phase 1 [94]
External Link
TTD: DTR05Z
 Compound Name CD38 CAR-T Phase 1 [95]
External Link
TTD: DSWZ60
 Compound Name RG6538 Phase 1 [96]
External Link
TTD: DS86KN
 Compound Name UCARTCS1 Phase 1 [97]
External Link
TTD: DS6W8Z
 Compound Name MB-104 Phase 1 [98]
External Link
TTD: DRU0M6
 Compound Name JNJ-79635322 Phase 1 [99]
Synonyms
JNJ-5322
    Click to Show/Hide
External Link
TTD: DRFS19
 Compound Name VOB560 Phase 1 [100]
Synonyms
S 65487
    Click to Show/Hide
External Link
TTD: DP63FS
 Compound Name CC-93269 Phase 1 [7]
Synonyms
BCMA TCE
    Click to Show/Hide
External Link
TTD: DOQ13X
 Compound Name AMG 424 Phase 1 [101]
External Link
TTD: DLY65X
 Compound Name 225Ac-labelled aCD38 Phase 1 [102]
External Link
TTD: DK1PA2
 Compound Name CC-99712 Phase 1 [103]
External Link
TTD: DH5BX2
 Compound Name MEDI2228 Phase 1 [104]
External Link
TTD: DG80IS
 Compound Name AMG 701 Phase 1 [7]
External Link
TTD: DF43EH
 Compound Name KP1237 Phase 1 [105]
Synonyms
BHV-1100
    Click to Show/Hide
External Link
TTD: DECJ17
 Compound Name CTX120 Phase 1 [106]
External Link
TTD: DE49RW
 Compound Name RG6296 Phase 1 [107]
Synonyms
AFM-26
    Click to Show/Hide
External Link
TTD: DC3Y7O
 Compound Name WVT078 Phase 1 [108]
External Link
TTD: D81YIK
 Compound Name M3258 Phase 1 [109]
Synonyms
LMP7-IN-1; 2285330-15-4; NSC818432; NSC-818432; HY-111790; CS-0091883; ((R)-2-(Benzofuran-3-yl)-1-((1S,2R,4R)-7-oxabicyclo[2.2.1]heptane-2-carboxamido)ethyl)boronic acid
    Click to Show/Hide
External Link
CID: 138319683
TTD: D7X8AQ
 Compound Name FT538 Phase 1 [110]
External Link
TTD: D79JZU
 Compound Name RG6234 Phase 1 [96]
External Link
TTD: D6RT9L
 Compound Name NAM-NK cells Phase 1 [111]
External Link
TTD: D6N8UJ
 Compound Name PHE885 Phase 1 [112]
External Link
TTD: D67ZDJ
 Compound Name ABBV-467 Phase 1 [113]
External Link
TTD: D63QIY
 Compound Name ALLO-715 Phase 1 [114]
External Link
TTD: D5YN8U
 Compound Name TTI-622 Phase 1 [115]
External Link
TTD: D5FCP1
 Compound Name SEA-BCMA Phase 1 [116]
External Link
TTD: D4QZ3O
 Compound Name FOR46 Phase 1 [117]
External Link
TTD: D48ZBO
 Compound Name CART-ddBCMA Phase 1 [118]
External Link
TTD: D3T7NY
 Compound Name TAK-169 Phase 1 [119]
External Link
TTD: D2HE9I
 Compound Name CT053 Phase 1 [120]
External Link
TTD: D1WOX4
 Compound Name RO6870810 Phase 1 [121]
Synonyms
JQ-35, (S)-; (S)-JQ-35; 1349719-98-7; (S)-JQ35; Bet inhibitor TEN-010; UNII-TA3QN7788D; TA3QN7788D; TEN-010; Ro-6870810; (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(3-(4-methylpiperazin-1-yl)propyl)acetamide; SCHEMBL881288; TEN010; CHEMBL4297423; Rg 6146; EX-A3890; NSC816555; DB15151; NSC-816555; SB19675; HY-117286; CS-0064969; Q27896195; C1CN(C)CCN1CCCNC(=O)C[C@H]1C2=NN=C(C)N2C(SC(C)=C2C)=C2C(C=2C=CC(Cl)=CC=2)=N1; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-chlorophenyl)-2,3,9-trimethyl-N-(3-(4-methyl-1-piperazinyl)propyl)-, (6S)-
    Click to Show/Hide
External Link
CID: 54670351
TTD: D15ZUR
DrugBank: DB15151
 Compound Name HPN217 Phase 1 [122]
External Link
TTD: D12DYT
 Compound Name TAK-573 Phase 1 [7]
External Link
TTD: D0ZDP2
 Compound Name PT-112 Phase 1 [7]
External Link
TTD: D0YJ5F
 Compound Name Anti-CD38 CAR-T cell therapy Phase 1 [7]
External Link
TTD: D0Y7LV
 Compound Name Actimab-M Phase 1 [33]
Synonyms
Actinium-225; Actinium, isotope of mass 225; 225Ac; AC1L4Z7V; 14265-85-1
    Click to Show/Hide
External Link
CID: 167045
TTD: D0XE4W
 Compound Name Anti-BCMA CAR T cells Phase 1 [123]
External Link
TTD: D0W7AB
 Compound Name BB-MPI-03 Phase 1 [46]
External Link
TTD: D0W1TL
 Compound Name Anti-FGFR3 Phase 1 [124]
External Link
TTD: D0V0BO
 Compound Name Anti-CD19/BCMA CAR-T cells Phase 1 [125]
External Link
TTD: D0U7WY
 Compound Name MTV273 Phase 1 [7]
External Link
TTD: D0U4KJ
 Compound Name Anti-BCMA CAR T cells Phase 1 [126]
External Link
TTD: D0U2PU
 Compound Name BCMA nanobody CAR-T cells Phase 1 [127]
External Link
TTD: D0T9CE
 Compound Name BCMA CART and huCART19 Phase 1 [128]
External Link
TTD: D0T8RV
 Compound Name SGN-CD48A Phase 1 [7]
External Link
TTD: D0S5CY
 Compound Name BCMA CART Phase 1 [128]
External Link
TTD: D0RD0D
 Compound Name Anti-BCMA CART Cells Phase 1 [129]
External Link
TTD: D0RA7L
 Compound Name APO-010 Phase 1 [130]
Synonyms
MegaFasL; Anticancer therapeutics (FasL), APoxis; Cancer therapeutics (FasL), Apoxis; Soluble FasL (Mega-Ligand), Apoxis; Soluble FasL (Mega-Ligand), TopoTarget
    Click to Show/Hide
External Link
TTD: D0Q6SF
 Compound Name Anti-BCMA CAR-T cell therapy Phase 1 [33]
External Link
TTD: D0O7XA
 Compound Name CC-115 Phase 1 [131]
Synonyms
CC-115 (hydrochloride); CC-115 hydrochloride; 1300118-55-1; SCHEMBL1767621; BCP20709; HY-16962A; AKOS030526389
    Click to Show/Hide
External Link
CID: 58298318
TTD: D0O1IM
DrugBank: DB12740
 Compound Name P-BCMA-101 CAR-T cells Phase 1 [132]
External Link
TTD: D0NK6K
 Compound Name BCMA CAR-T Cells Phase 1 [133]
External Link
TTD: D0NG3T
 Compound Name CM-CS1 T-cell Phase 1 [134]
External Link
TTD: D0NC9M
 Compound Name Mivebresib Phase 1 [7]
Synonyms
ABBV-075; 1445993-26-9; UNII-VR86R11J7J; VR86R11J7J; N-[4-(2,4-Difluorophenoxy)-3-(6-Methyl-7-Oxo-6,7-Dihydro-1h-Pyrrolo[2,3-C]pyridin-4-Yl)phenyl]ethanesulfonamide; N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide; 8NG; Mivebresib [INN]; ABBV-075 (Mivebresib); ABBV075; GTPL9117; SCHEMBL15068241; CHEMBL3987016; Mivebresib(ABBV-075 pound(c); MolPort-044-561-801; RDONXGFGWSSFMY-UHFFFAOYSA-N; BDBM220447; EX-A1082; s8400; ZINC146486516; AKOS030628486; CS-5815
    Click to Show/Hide
External Link
CID: 71600087
TTD: D0M2TS
 Compound Name PF-06688992 Phase 1 [33]
External Link
TTD: D0JB9C
 Compound Name DFRF4539A Phase 1 [135]
External Link
TTD: D0J9YS
 Compound Name C-CAR088 Phase 1 [136]
External Link
TTD: D0J7OU
 Compound Name AMG 176 Phase 1 [7]
Synonyms
JQNINBDKGLWYMU-GEAQBIRJSA-N; AMG-176; 1883727-34-1; AMG176; SCHEMBL17550216; EX-A2666; HY-101565; CS-0021721; Spiro[5,7-etheno-1H,11H-cyclobut[i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-2(3H),1'(2'H)-naphthalen]-8(9H)-one, 6'-chloro-3',4',12,13,16,16a,17,18,18a,19-decahydro-16-methoxy-11,12-dimethyl-,10,10-dioxide, (1'S,11R,12S,14E,16S,16aR,18aR)-
    Click to Show/Hide
External Link
CID: 118910268
TTD: D0I5DP
 Compound Name LCAR-B4822M CAR-T Cell Phase 1 [137]
External Link
TTD: D0I1PF
 Compound Name Natural killer cell therapy Phase 1 [138]
Synonyms
Killer cell therapy; Natural killer cell therapy (autologous, multiple myeloma)
    Click to Show/Hide
External Link
TTD: D0H6FY
 Compound Name VLX1570 Phase 1 [31]
Synonyms
SCKXBVLYWLLALY-ZSIIYVIPSA-N; VLX-1570; 1431280-51-1; BCP18900
    Click to Show/Hide
External Link
CID: 71523377
TTD: D0G7IF
 Compound Name STRO-001 Phase 1 [7]
External Link
TTD: D0E7FC
 Compound Name JNJ-64407564 Phase 1 [7]
External Link
TTD: D0DA4B
 Compound Name KITE-585 Phase 1 [7]
External Link
TTD: D0C8QA
 Compound Name ABBV-838 Phase 1 [33]
External Link
TTD: D0BB2V
 Compound Name CAR-T cells targeting BCMA Phase 1 [139]
External Link
TTD: D0B2WU
 Compound Name CAR138 T Cells Phase 1 [140]
External Link
TTD: D09ZDY
 Compound Name SGN-CD352A Phase 1 [7]
External Link
TTD: D09RUO
 Compound Name CB-5083 Phase 1 [141]
External Link
CID: 73051434
TTD: D08OOJ
 Compound Name AEW-541 Phase 1 [142]
Synonyms
AECDBHGVIIRMOI-UHFFFAOYSA-N; NVP-AEW541; 475489-16-8; 475488-34-7; AEW541; NVP-AEW 541; UNII-97QB5037VR; AEW 541; AVP-AEW541; 7-((1s,3s)-3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-(benzyloxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; CHEMBL1614712; 97QB5037VR; 7-[TRANS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE; C27H29N5O; 7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE, 7-[CIS-3-(1-AZETIDINYLMETHYL)CYCLOBUTYL]-5-[3-(PHENYLMETHOXY)PHENYL]-
    Click to Show/Hide
External Link
CID: 11476171
TTD: D07HPJ
 Compound Name Anti-BCMA CAR-T cells Phase 1 [143]
External Link
TTD: D07HJS
 Compound Name IM21 CART Phase 1 [144]
External Link
TTD: D05XNF
 Compound Name Anti-CD38 CAR-T cells Phase 1 [145]
External Link
TTD: D05WET
 Compound Name ATA520 Phase 1 [33]
External Link
TTD: D05MVX
 Compound Name GRN163 Phase 1 [21]
External Link
CID: 56603713
TTD: D04HDZ
 Compound Name GBR 1342 Phase 1 [7]
External Link
TTD: D04GAG
 Compound Name ACTR-BCMA Phase 1 [7]
Synonyms
ACTR087 + SEA-BCMA
    Click to Show/Hide
External Link
TTD: D03XFH
 Compound Name CC-122 Phase 1 [7]
Synonyms
1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995
    Click to Show/Hide
External Link
CID: 24967599
TTD: D03QZJ
DrugBank: DB14857
 Compound Name PNK-007 Phase 1 [7]
External Link
TTD: D03IRG
 Compound Name Anti-CD19 CART Cells Phase 1 [129]
External Link
TTD: D02NFE
 Compound Name BFCR4350A Phase 1 [7]
Synonyms
RG6160
    Click to Show/Hide
External Link
TTD: D02HFN
 Compound Name CART-BCMA Phase 1 [146]
External Link
TTD: D01YZF
 Compound Name Citarinostat Phase 1 [7]
Synonyms
ACY-241; 1316215-12-9; HDAC-IN-2; 2-((2-Chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide; UNII-441P620G3P; 441P620G3P; Citarinostat [USAN]; Citarinostat (USAN); 2-(N-(2-chlorophenyl)anilino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide; 2-((2-Chlorophenyl)phenylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-5-pyrimidinecarboxamide; 2-[(2-Chlorophenyl)phenylamino]-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide; Citarinostat (ACY-241); SCHEMBL2225863; GTPL942
    Click to Show/Hide
External Link
CID: 53340426
TTD: D01WKZ
DrugBank: DB15449
 Compound Name NAM-NK cells + IL-2 Phase 1 [7]
External Link
TTD: D01PXH
 Compound Name PF-06863135 Phase 1 [7]
External Link
TTD: D01JSI
 Compound Name AMG 224 Phase 1 [7]
External Link
TTD: D01EXG
 Compound Name CART-19 T cells Phase 1 [147]
External Link
TTD: D00YUQ
 Compound Name Bb21217 Phase 1 [148]
External Link
TTD: D00OXP
 Compound Name CAR-T cells targeting CD56 Clinical trial [149]
External Link
TTD: D0V6WW
 Compound Name CAR-T cells targeting CD38 Clinical trial [149]
External Link
TTD: D0V6WU
 Compound Name CAR-T cells targeting CD138 Clinical trial [149]
External Link
TTD: D0T6NG
 Compound Name CAR-BCMA T cell Clinical trial [150]
External Link
TTD: D0PF1A
 Compound Name BCMA-UCART Clinical trial [151]
External Link
TTD: D0N8NT
 Compound Name CAR-T cells targeting BCMA Clinical trial [149]
External Link
TTD: D0LP1L
 Compound Name BCMA-CART Clinical trial [152]
External Link
TTD: D09ZGK
 Compound Name RG7598 Discontinued in Phase 1 [153]
External Link
TTD: D0S3BR
 Compound Name AS602868 Discontinued in Phase 1 [154]
Synonyms
Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin
    Click to Show/Hide
External Link
CID: 9820526
TTD: D01OLO
 Compound Name UCART-CLL1 Preclinical [155]
External Link
TTD: DIW58H
 Compound Name 211At-labelled aLAT-1 Preclinical [156]
External Link
TTD: D2J4YT
 Compound Name P-BCMA-ALL01 Preclinical [157]
External Link
TTD: D01SNU
 Compound Name zoxazolamine Terminated [158]
Synonyms
61-80-3; 2-Amino-5-chlorobenzoxazole; 5-chlorobenzo[d]oxazol-2-amine; 5-Chloro-1,3-benzoxazol-2-amine; Flexin; 2-Benzoxazolamine, 5-chloro-; Contrazole; Deflexol; Flexilon; Zoxamin; Zoxine; USAF MA-12; McN-485; 5-Chloro-2-benzoxazolamine; Zossazolamina [DCIT]; C7H5ClN2O; Zoxazolaminum [INN-Latin]; Zoxazolamina [INN-Spanish]; NSC 24995; UNII-9DOW362Q29; BENZOXAZOLE, 2-AMINO-5-CHLORO-; CHEBI:35053; EINECS 200-519-4; MLS002639033; AI3-63120; YGCODSQDUUUKIV-UHFFFAOYSA-N; 9DOW362Q29; 2-Amino-5-chlorobenzoxazole, 97%
    Click to Show/Hide
External Link
CID: 6103
TTD: D0N0LB
 Compound Name AG490 Terminated [159]
Synonyms
(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665
    Click to Show/Hide
External Link
CID: 5328779
TTD: D0GZ7B
 Compound Name G3139 + Dexamethasone Investigative [160]
External Link
CID: 91865905
TTD: D0W8ZE
 Compound Name GNE-652 Investigative [161]
Synonyms
PIM kinase inhibitor (multiple myeloma), Genentech
    Click to Show/Hide
External Link
TTD: D0U2OS
 Compound Name CCX-721 Investigative [161]
Synonyms
CCR1 antagonist (myeloma), ChemoCentryx
    Click to Show/Hide
External Link
TTD: D0P8HU
 Compound Name JB-1 Investigative [21]
Synonyms
JB1
    Click to Show/Hide
External Link
CID: 25150849
TTD: D0O0RY
 Compound Name BIBF100 Investigative [21]
External Link
TTD: D0N1RE
 Compound Name BAY11-7082 Investigative [162]
Synonyms
bay 11-7082; 19542-67-7; (E)-3-Tosylacrylonitrile; Bay 11-7821; (E)-3-(p-Toluenesulfonyl)acrylonitrile; BAY-11-7082; UNII-4Y5G2A4F6O; BAY-11-7821; (E)-3-(4-Methylphenyl)sulfonylprop-2-enenitrile; BAY-117082; BAY-117821; CHEMBL403183; 4Y5G2A4F6O; 3-(4-methylphenylsulfonyl)-2-propenenitrile; CHEBI:85928; 3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile; AK129348; (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile; (E)3-[(4-Methylphenyl)sulfonyl]-2-propenenitrile; J-501956; (2E)-3-[(4-methylphenyl)sulfonyl]prop-2-enenitrile
    Click to Show/Hide
External Link
CID: 5353431
TTD: D0L2XO
 Compound Name UCL-67022 Investigative [163]
Synonyms
HDAC inhibitor (multiple myeloma), ST Barts/UCL
    Click to Show/Hide
External Link
TTD: D0L0LR
 Compound Name AbGn-150 Investigative [161]
Synonyms
Antibody-150
    Click to Show/Hide
External Link
TTD: D0I6UN
 Compound Name ACHP Investigative [21]
External Link
CID: 135465539
TTD: D0F0VD
 Compound Name SU5402 Investigative [21]
Synonyms
215543-92-3; SU 5402; SU-5402; 3-[3-(2-Carboxyethyl)-4-methylpyrrol-2-methylidenyl]-2-indolinone; (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; CHEMBL89363; 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE; J-502595; 3-{[3-(2-carboxyethyl)-4-methylpyrrol-2-yl]methylene}-2-indolinone; 3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid; (Z)-3-(4-Methyl-2-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid
    Click to Show/Hide
External Link
CID: 5289418
TTD: D0A4XJ
DrugBank: DB08577
 Compound Name TP-110 Investigative [161]
Synonyms
Tyropeptin A derivatives, Microbial Chemistry Research Foundation; Proteasome inhibitors (cancer), Microbial Chemistry Research Foundation
    Click to Show/Hide
External Link
CID: 11592579
TTD: D0A4VW
 Compound Name TMPyP4 Investigative [21]
Synonyms
TMPP; AC1L1HPJ; N-Methylpyridylylporphyrin; AC1Q29RK; CHEMBL65606; ABCGFHPGHXSVKI-UHFFFAOYSA-O; BDBM50107609; 4,4',4'',4'''-(5,10,15,20-porphyrintetrayl)tetrakis(1-methylpyridinium); J2.096.016G; 5,10,15,20-tetra(1-methyl-4-pyridyl)-porphyrin; 5,10,15,20-tetrakis(1-methylpyridin-1-ium-4-yl)-21,22-dihydroporphyrin
    Click to Show/Hide
External Link
CID: 135398505
TTD: D08UZL
 Compound Name Sant7 Investigative [21]
Synonyms
beta-Methylene tad; BETA-METHYLENE-THIAZOLE-4-CARBOXYAMIDE-ADENINE DINUCLEOTIDE; 102977-57-1; beta-Tad; NSC617998; 1lrt; NSC 617998; beta-Methylene thiazole-4-carboxamide adenine dinucleotide; .beta.-Methylene TAD; AC1L2TER; Adenosine, 5'-(hydrogen (phosphonomethyl)phosphonate), 5'-ester with 2-beta-D-ribofuranosyl-4-thiazolecarboxamide
    Click to Show/Hide
External Link
CID: 128225
TTD: D07VQW
 Compound Name PS-1145 Investigative [21]
Synonyms
431898-65-6; PS 1145; CHEMBL79004; N-(6-Chloro-9H-beta-carbolin-8-yl)-nicotinamide; MLS006010310; ZINC9090; SCHEMBL1420453; CTK1D2755; KS-00000TTM; CHEBI:94801; DTXSID00433238; EX-A786; MolPort-042-665-715; JZRMBDHPALEPDM-UHFFFAOYSA-N; HMS3229F21; BCP24095; s7691; BDBM50130248; AKOS030526812; CS-5415; ACN-053038; NCGC00165873-02; NCGC00165873-01; SMR004701376; HY-18008; AK547800; FT-0700478; J-690297; BRD-K93023739-001-02-9; N-{6-chloro-9H-pyrido[3,4-b]indol-8-yl}pyridine-3-carboxamide
    Click to Show/Hide
External Link
CID: 9949093
TTD: D07MQC
 Compound Name FM-101 Investigative [164]
External Link
TTD: D07CIX
 Compound Name NVP-ADW742 Investigative [21]
Synonyms
475488-23-4; ADW-742; 475489-15-7; UNII-MXS2N5862L; ADW742; MXS2N5862L; CHEMBL399021; 5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(3-(Benzyloxy)phenyl)-7-(cis-3-(pyrrolidin-1-ylmethyl)cyclobutyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine; C28H31N5O; 5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
    Click to Show/Hide
External Link
CID: 9825149
TTD: D06NMZ
 Compound Name CGEN-928 Investigative [161]
Synonyms
Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment); Anti-TM21 polyclonal antibody (multiple myeloma treatment), Compugen; CGEN-928 (multiple myeloma treatment), Compugen; Anti-CGEN-928 polyclonal antibody (multiple myeloma treatment), Compugen
    Click to Show/Hide
External Link
TTD: D04VUM
 Compound Name Tubacin Investigative [165]
Synonyms
537049-40-4; AC1O7Y2P; CHEMBL356769; 1350555-93-9; N1-(4-((2R,4R,6S)-4-(((4,5-Diphenyloxazol-2-yl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxyoctanediamide; Tubacin (BML-GR362); Octanediamide, N1-(4-((2R,4R,6S)-4-(((4,5-diphenyl-2-oxazolyl)thio)methyl)-6-(4-(hydroxymethyl)phenyl)-1,3-dioxan-2-yl)phenyl)-N8-hydroxy-, rel-; N-[4-[(2R,4R,6S)-4-[[(4,5-Diphenyl-2-oxazolyl)thio]methyl]-6-[4-(hydroxymethyl)phenyl]-1,3-dioxan-2-yl]phenyl]-N'-hydroxyoctanediamide; SCHEMBL4741166
    Click to Show/Hide
External Link
CID: 6675804
TTD: D04KQF
 Compound Name Anti-HM1.24 Investigative [161]
External Link
TTD: D01LZB
 Compound Name Telomestatin Investigative [21]
Synonyms
YVSQVYZBDXIXCC-UHFFFAOYSA-N; AC1L9EVW; CHEMBL443683; CHEBI:29689; Telomestatin (TMS); gm95; SureCN10025441; SCHEMBL10025441; CHEBI:601758; BDBM213233; DCL000983
    Click to Show/Hide
External Link
CID: 443590
TTD: D01GEO
 Compound Name G3139 + Thalidomide Investigative [160]
External Link
CID: 91865905
TTD: D00DDR
References
Ref 1 LncRNA HOXB-AS1 promotes cell growth in multiple myeloma via FUT4 mRNA stability by ELAVL1. J Cell Biochem. 2020 Oct;121(10):4043-4051. doi: 10.1002/jcb.29573. Epub 2019 Dec 30.
Ref 2 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
Ref 3 ClinicalTrials.gov (NCT05461209) A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma Who Have Received at Least 4 Prior Therapies Including an Immunomodulatory Drug, a Proteasome Inhibitor, and an Anti-CD38 Antibody. U.S.National Institutes of Health.
Ref 4 ClinicalTrials.gov (NCT04126200) Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5). U.S. National Institutes of Health.
Ref 5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 6 ClinicalTrials.gov (NCT05014412) A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOSES AND LONGER DOSING INTERVALS OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. U.S.National Institutes of Health.
Ref 7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 8 ClinicalTrials.gov (NCT02051842) Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis. U.S. National Institutes of Health.
Ref 9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015
Ref 10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7327).
Ref 11 ClinicalTrials.gov (NCT03246529) A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS). U.S. National Institutes of Health.
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
Ref 13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7395).
Ref 14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
Ref 15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
Ref 16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5678).
Ref 17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 18 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8361).
Ref 19 ClinicalTrials.gov (NCT03651128) Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3). U.S. National Institutes of Health.
Ref 20 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 21 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 22 ClinicalTrials.gov (NCT04557098) A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 23 ClinicalTrials.gov (NCT02052778) A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities. U.S. National Institutes of Health.
Ref 24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5056).
Ref 25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8450).
Ref 26 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7420).
Ref 28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7620).
Ref 29 ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
Ref 30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8000).
Ref 31 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 32 Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661.
Ref 33 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 34 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8269).
Ref 35 ClinicalTrials.gov (NCT01659580) Phase III Trial of Dantonic (T89) Capsule to Prevent and Treat Stable Angina. U.S. National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT02426086) Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT04436029) Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT01711671) A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 39 ClinicalTrials.gov (NCT04176380) RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 40 ClinicalTrials.gov (NCT01302886) Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma. U.S. National Institutes of Health.
Ref 41 ClinicalTrials.gov (NCT04582539) To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.. U.S. National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT04816526) Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy. U.S. National Institutes of Health.
Ref 43 Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Curr Cancer Drug Targets. 2014;14(6):517-36.
Ref 44 ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
Ref 45 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7751).
Ref 46 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 47 ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Ref 48 ClinicalTrials.gov (NCT02794246) CART-19 Post-ASCT for Multiple Myeloma
Ref 49 Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.
Ref 50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035081)
Ref 51 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 021430
Ref 52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032606)
Ref 53 ClinicalTrials.gov (NCT01854034) Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR. U.S. National Institutes of Health.
Ref 54 Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled (Propylene Glycol-Free) Melphalan. Spectrum Pharmaceuticals. October 23, 2015.
Ref 55 ClinicalTrials.gov (NCT01222286) Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma. U.S. National Institutes of Health.
Ref 56 ClinicalTrials.gov (NCT00421213) Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers. U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT02318368) A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label. U.S. National Institutes of Health.
Ref 58 Clinical pipeline report, company report or official report of Aduro.
Ref 59 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7933).
Ref 60 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7890).
Ref 61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022911)
Ref 62 ClinicalTrials.gov (NCT04083534) First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM). U.S. National Institutes of Health.
Ref 63 ClinicalTrials.gov (NCT03761108) First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 64 ClinicalTrials.gov (NCT03309111) Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma. U.S. National Institutes of Health.
Ref 65 ClinicalTrials.gov (NCT04171843) A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A in Study Participants With Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 66 ClinicalTrials.gov (NCT04505813) Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 67 ClinicalTrials.gov (NCT03687125) Phase 1/2 Open-label Trial of Tinostamustine Conditioning and Autologous Stem Cell Transplantation for Salvage Treatment in Relapsed / Refractory Multiple Myeloma (TITANIUM 1). U.S.National Institutes of Health.
Ref 68 ClinicalTrials.gov (NCT05590377) A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.
Ref 69 ClinicalTrials.gov (NCT01101594) A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma. U.S. National Institutes of Health.
Ref 70 ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma
Ref 71 ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
Ref 72 ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Ref 73 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 74 ClinicalTrials.gov (NCT01421186) A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 75 ClinicalTrials.gov (NCT01898156) Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer. U.S. National Institutes of Health.
Ref 76 ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
Ref 77 ClinicalTrials.gov (NCT03374085) A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM). U.S. National Institutes of Health.
Ref 78 ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma
Ref 79 ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
Ref 80 ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
Ref 81 ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
Ref 82 ClinicalTrials.gov (NCT03741127) Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Ref 83 ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies
Ref 84 ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Ref 85 Clinical pipeline report, company report or official report of Arno Therapeutics.
Ref 86 ClinicalTrials.gov (NCT02144038) Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 87 ClinicalTrials.gov (NCT01232712) A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies. U.S. National Institutes of Health.
Ref 88 ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma
Ref 89 ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 90 ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 91 ClinicalTrials.gov (NCT03933735) A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 92 ClinicalTrials.gov (NCT02278315) Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 93 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
Ref 94 ClinicalTrials.gov (NCT04162353) BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma. U.S. National Institutes of Health.
Ref 95 Clinical pipeline report, company report or official report of Sorrento Therapeutics.
Ref 96 Clinical pipeline report, company report or official report of Roche
Ref 97 ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.
Ref 98 ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma. U.S. National Institutes of Health.
Ref 99 ClinicalTrials.gov (NCT05652335) Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis. U.S.National Institutes of Health.
Ref 100 ClinicalTrials.gov (NCT04702425) VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma). U.S. National Institutes of Health.
Ref 101 ClinicalTrials.gov (NCT03445663) Study Evaluating AMG 424 in Subjects With Multiple Myeloma. U.S. National Institutes of Health.
Ref 102 ClinicalTrials.gov (NCT02998047) A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 103 ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 104 ClinicalTrials.gov (NCT03489525) MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma (MEDI2228). U.S. National Institutes of Health.
Ref 105 ClinicalTrials.gov (NCT04634435) A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 (Formerly KP1237) and IVIG Followed by Low Dose IL-2 as Early Post-Autologous Transplant Consolidation in Minimal Residual Disease Positive, Multiple Myeloma (MM) Patients in First or Second Remission. U.S.National Institutes of Health.
Ref 106 ClinicalTrials.gov (NCT04244656) A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 107 ClinicalTrials.gov (NCT04434469) A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 108 ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health.
Ref 109 ClinicalTrials.gov (NCT04075721) First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone. U.S. National Institutes of Health.
Ref 110 ClinicalTrials.gov (NCT04614636) FT538 in Subjects With Advanced Hematologic Malignancies. U.S. National Institutes of Health.
Ref 111 ClinicalTrials.gov (NCT03019666) Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL. U.S. National Institutes of Health.
Ref 112 ClinicalTrials.gov (NCT04318327) BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 113 ClinicalTrials.gov (NCT04178902) A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma. U.S. National Institutes of Health.
Ref 114 ClinicalTrials.gov (NCT04093596) Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL) (UNIVERSAL). U.S. National Institutes of Health.
Ref 115 ClinicalTrials.gov (NCT03530683) A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma (TTI-622-01). U.S. National Institutes of Health.
Ref 116 ClinicalTrials.gov (NCT03582033) A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma. U.S.National Institutes of Health.
Ref 117 ClinicalTrials.gov (NCT03650491) A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM). U.S. National Institutes of Health.
Ref 118 Clinical pipeline report, company report or official report of Arcellx.
Ref 119 ClinicalTrials.gov (NCT04017130) A Study of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 120 ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health.
Ref 121 ClinicalTrials.gov (NCT03068351) Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma. U.S. National Institutes of Health.
Ref 122 ClinicalTrials.gov (NCT04184050) A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM. U.S. National Institutes of Health.
Ref 123 ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Ref 124 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 125 ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM
Ref 126 ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma
Ref 127 ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
Ref 128 ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
Ref 129 ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
Ref 130 APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64. doi: 10.1093/neuonc/noq176. Epub 2010 Dec 22.
Ref 131 ClinicalTrials.gov (NCT01353625) Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.. U.S. National Institutes of Health.
Ref 132 ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
Ref 133 ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
Ref 134 ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Ref 135 ClinicalTrials.gov (NCT01432353) A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
Ref 136 ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
Ref 137 ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
Ref 138 Clinical pipeline report, company report or official report of Karolinska Institute.
Ref 139 ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma
Ref 140 ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
Ref 141 ClinicalTrials.gov (NCT02243917) A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 142 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019974)
Ref 143 ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma
Ref 144 ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
Ref 145 ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
Ref 146 ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma
Ref 147 ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma
Ref 148 ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma
Ref 149 ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
Ref 150 ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Ref 151 ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART
Ref 152 ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
Ref 153 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035041)
Ref 154 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009941)
Ref 155 Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199.
Ref 156 Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.
Ref 157 Clinical pipeline report, company report or official report of Poseida Therapeutics.
Ref 158 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2327).
Ref 159 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5916).
Ref 160 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
Ref 161 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 162 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5934).
Ref 163 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2618).
Ref 164 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310).
Ref 165 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7374).